Cipla Ltd

Cipla Limited

Cipla Limited has informed BSE about the cessation of Global Head Supply Chain.

Cipla Limited

Cipla Limited has informed BSE about the cessation of Global Head Supply Chain.

Cipla Limited

Cipla Limited has informed BSE about the cessation of Global Head Supply Chain.

Cipla Limited

Cipla Limited has informed BSE about the cessation of Global Head Supply Chain.

Cipla Limited

Cipla Limited has informed BSE about the cessation of Global Head Supply Chain.

Cipla Limited

Cipla Limited has informed BSE about the cessation of its Global Head Supply Chain.

Cipla Ltd

Cipla Ltd has announced a change in management with Mr. Venkata Sai Mungara transitioning to a new role at Cipla USA Inc., a wholly owned subsidiary, effective October 1, 2026. He will cease to be a Senior Management Personnel of the Company.

Cipla Ltd

Cipla Ltd has announced an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to Keytruda (Pembrolizumab) in the US.

Cipla Ltd

Cipla Ltd has received an order from the National Company Law Tribunal (NCLT) to merge Inzpera Healthsciences Limited with the company. The company has sent notices to shareholders and creditors, providing an opportunity to submit representations within 30 days.

Cipla Ltd

Cipla Ltd has announced the opening of a special window for re-lodgement of transfer and dematerialisation of physical shares, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Cipla Ltd

Cipla Ltd has entered into an exclusive licensing agreement with SBP Group for the development and commercialization of Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC, in India, South Africa, and select emerging markets.

Cipla Ltd

Cipla Ltd has received a Voluntary Action Indicated (VAI) classification from the USFDA following an inspection at its InvaGen manufacturing facility in Central Islip, Long Island, NY, USA.

Cipla Ltd

Cipla Ltd has announced a restructuring of its group structure by acquiring 100% stake in Aspergen Inc., USA, a step-down subsidiary, through its 60:40 joint venture Aspergen Limited, India. The move aims to rationalise and simplify the group structure, with no change in the Company's economic interest in Aspergen Inc., USA.

Cipla Ltd

Cipla Ltd has announced the schedule of Analyst / Institutional Investor Meetings with the Company, to be held on 17th September 2026 at Jefferies India Forum Conference in Gurgaon and 18th September 2026 at Kotak Healthcare Conference in Mumbai.

Cipla Ltd

Cipla Ltd has allotted 5,281 fully paid-up equity shares under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing its issued, subscribed and paid-up share capital to INR 1,61,57,16,894.

Cipla Ltd

Cipla Ltd has received 7 inspectional observations from the USFDA following a follow-up cGMP inspection at its Pithampur, India manufacturing facility. The company will address these observations within the stipulated time.

Cipla Ltd

Cipla Ltd has informed the exchange about receipt of order from Hon'ble NCLT, Mumbai Bench regarding the Scheme of Amalgamation of Inzpera Healthsciences Limited with Cipla Limited.

Cipla Ltd

Cipla Ltd has been assigned ESG ratings by SES ESG Research Private Limited and NSE Sustainability Ratings & Analytics Limited. SES assigned a rating of 69.9 (Grade B) for FY 2025-26, while NSE assigned a rating of 67 (Aspiring) for the same period. The decline in NSE rating is attributed to a product recall by Cipla USA Inc. in January 2026.

Cipla Ltd

Cipla Ltd has received the Establishment Inspection Report (EIR) from the USFDA, indicating the closure of the inspection at its InvaGen manufacturing facility in Hauppauge, Long Island, New York, USA.

Cipla Ltd

Cipla Ltd has allotted 7,850 fully paid-up equity shares under the Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the issued, subscribed and paid-up share capital to INR 1,61,57,06,332.